CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA
interference (RNAi) therapeutics, today announced that Douglas M.
Fambrough, Ph.D., president and chief executive officer, will present at
the Leerink Partners 4th Annual Rare Disease Roundtable. The
presentation will take place on Wednesday, September 30, 2015 at 10:40
a.m. ET at Le Parker Meridien Hotel in New York City.
A live webcast of the presentation can be accessed by visiting "Events
& Presentations" in the Investors and Media section on the
Company's website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative treatments for rare,
inherited diseases involving the liver and for cancers that are
genetically defined. The company is using its proprietary RNA
interference (RNAi) technology platform to build a broad pipeline in
these therapeutic areas. In both rare diseases and oncology, Dicerna is
pursuing targets that have been difficult to address using conventional
approaches, but where connections between targets and diseases are well
understood and documented. The company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150924006496/en/
Alex Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media